Daniel Heudobler

Franz Josef Strauß Allee 11
Regensburg, BY 93053, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

Journal: Nature medicine

Published: June 19, 2026

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

Journal: Nature medicine

Published: April 17, 2026

Editorial: Exploiting non-oncogene addiction for overcoming drug resistance in metastatic tumors.

Editorial: Exploiting non-oncogene addiction for overcoming drug resistance in metastatic tumors.

Journal: Frontiers in pharmacology

Published: January 28, 2026

Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study.

Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study.

Journal: Cancer research communications

Published: January 14, 2026

Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine Plus Pioglitazone and All-Trans Retinoic Acid.

Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine Plus Pioglitazone and All-Trans Retinoic Acid.

Journal: International journal of molecular sciences

Published: December 23, 2025

How to improve informed consent processes in clinical trials with cancer patients: a qualitative analysis of multidisciplinary experts' perspectives.

How to improve informed consent processes in clinical trials with cancer patients: a qualitative analysis of multidisciplinary experts' perspectives.

Journal: BMC medical ethics

Published: July 17, 2025

Genome agnostic, multi-level non-oncogene addiction-based systems pharmacology for rescuing metastatic relapsed/refractory neoplasias.

Genome agnostic, multi-level non-oncogene addiction-based systems pharmacology for rescuing metastatic relapsed/refractory neoplasias.

Journal: Frontiers in pharmacology

Published: May 15, 2025

Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients.

Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients.

Journal: BMC medicine

Published: May 02, 2025

MetInfilt: A prospective trial highlighting the importance of the histological growth pattern in brain metastases.

MetInfilt: A prospective trial highlighting the importance of the histological growth pattern in brain metastases.

Journal: Translational oncology

Published: March 27, 2025

Primary and secondary metastatic dissemination: multiple routes to cancer-related death.

Primary and secondary metastatic dissemination: multiple routes to cancer-related death.

Journal: Molecular cancer

Published: February 07, 2025

Preliminary effectiveness of social prescription and virtual patient information in increasing tertiary prevention among cancer patients (ESPRIT): protocol for a single-centre, randomised controlled pilot trial.

Preliminary effectiveness of social prescription and virtual patient information in increasing tertiary prevention among cancer patients (ESPRIT): protocol for a single-centre, randomised controlled pilot trial.

Journal: BMJ open

Published: January 20, 2025

MEPED as salvage therapy for relapsed/refractory Hodgkin's lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck.

MEPED as salvage therapy for relapsed/refractory Hodgkin's lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck.

Journal: Frontiers in pharmacology

Published: December 30, 2024

Showing 1-12 of 53

Last Updated: 09/26/2026